~~<i id='F191FA9A7E'><strike id='F191FA9A7E'><tt id='F191FA9A7E'><pre id='F191FA9A7E'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：Wikipedia 2025-09-30 12:22:41 Page View：94434

It’s that time of the year again when I recognize the Best Biopharma CEO of the year.

This year’s selection is so deservingly obvious that I won’t fabricate suspense by starting with an honor roll of runners-up. More on those high-achieving folks later. Let’s get right to the main course: David Ricks of Eli Lillyis the runaway, rock star, who-else-could-it-be Best Biopharma CEO of 2023.

What an incredible year it’s been for Ricks and the Lilly executive team who helped him achieve so much. My colleague Matt Herper wrote earlier this year about the “dynamic duo” of Ricks and Chief Scientific Officer Dan Skovronsky.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： With Wegovy coverage, Medicare patients may face high costs
Next article： ChatGPT in medicine: STAT answers readers' burning questions

leisure time

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Diabetes management: Digital health tools fall short, study says

AdobeThelastdecadehasseenbillionsofdollarsflowintodigitalhealthcompaniesthatpromisetoimproveoutcomes

As demand for Covid shots wanes, Moderna seeks its next success

RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

Pfizer, Moderna say biotech, pharma drug development is a sprint

Fromlefttoright,STAT'sDamianGarde;MikaelDolsten,chiefscientificofficerofPfizerresearchanddevelopment